Filtered By:
Condition: Atrial Fibrillation
Countries: France Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 90 results found since Jan 2013.
Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers
CONCLUSIONS: The anonymous matching of an HF research cohort with a national health database is feasible, with a significant proportion of patients being accurately matched, and facilitates combination of clinical data and a reduced rate of losses to follow-up.PMID:36549971 | DOI:10.1016/j.acvd.2022.11.002
Source: Archives of Cardiovascular Diseases - December 22, 2022 Category: Cardiology Authors: Damien Logeart Thibaud Damy Maxime Doublet Muriel Salvat Christophe Tribouilloy Fabrice Bauer Jean-Christophe Eicher Fran çois Picard G érald Roul Jean-No ël Trochu Pascal De Groote Nicolas Bihry Emmanuelle Berthelot Guillaume Jondeau Marie-France Sero Source Type: research
Prediction of incident atrial fibrillation in post-stroke patients using machine learning: a French nationwide study
ConclusionsML algorithms predict incident AF post-stroke with a better ability than previously developed clinical scores.Graphic AbstractAF: atrial fibrillation; DNN: deep neural network; IS: ischemic stroke; KNN: K-nearest neighbors; LR: logistic regression; RFC: random forest classifier; XGBoost: extreme gradient boosting
Source: Clinical Research in Cardiology - December 17, 2022 Category: Cardiology Source Type: research
As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research
Comorbidities in patients with Obstructive Sleep Apnea syndrome (OSAS) in Reunion Island.
Conclusion: Morbid obesity, hypertension, diabetes, heart disease and respiratory illness are a predictor of severe OSAS in our patients especially snorers.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Omarjee, B., Budhan, S., Kichenin, C., Omarjee, A., Vellin, J. F. Tags: 01.01 - Clinical problems - no related to asthma or COPD Source Type: research
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study
CONCLUSIONS: In this nationwide observational study, non-persistence rates of oral anticoagulant treatment were high in patients treated for NVAF. Apixaban-treated patients seem to experience lowest discontinuation rates 12 months after treatment initiation compared to patients treated with any other OAC.PMID:36257903 | DOI:10.1016/j.acvd.2022.06.006
Source: Archives of Cardiovascular Diseases - October 18, 2022 Category: Cardiology Authors: Nicolas Danchin Gabriel Steg Isabelle Mah é Olivier Hanon Flore Jacoud Ma ëva Nolin Faustine Dalon Fran çois-Emery Cotte Sabrina Gollety Eric Van Ganse Manon Belhassen Source Type: research
